Dr. Permar and Dr. Acker detail two highly effective RSV vaccines that can safely reduce RSV disease in the first year of life. Both are currently under review for newborns. “The development of both RSV vaccines was led by pediatric researchers who understood the burden of disease for children caused by RSV,” they write. “But approval processes for crucial interventions for RSV have been lumbering, even as the next respiratory viral season looms.”
They conclude: “Pediatricians often have to be the voice for children. So we are asking on their behalf now: Make RSV vaccines for newborns available without delay and before they fill up pediatric emergency rooms and hospitals across the country.”
Read the full op-ed here.